Location: Chicago, IL
CIK: 0001274403 · Show all filings
Period: Q4 2022 (← Previous) (Next →)
Filing Date: Feb 14, 2023
Total Value: $390M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| DNLI | DENALI THERAPEUTICS, INC. | 3,668,749 | $102M | 26.1% | $26.20 | +13.6% | COM | 24823R105 |
| — | KARUNA THERAPEUTICS, INC. | 512,872 | $101M | 25.8% | $131.00 | — | COM | 48576A100 |
| — | EQRX, INC. | 36,335,375 | $89.39M | 22.9% | $6.82 | — | COM | 26886C107 |
| ERAS | ERASCA, INC. | 11,055,554 | $47.65M | 12.2% | $17.12 | -60.4% | COM | 29479A108 |
| — | VERVE THERAPEUTICS, INC. | 2,008,809 | $38.87M | 10.0% | $36.87 | — | COM | 92539P101 |
| — | SINGULAR GENOMICS SYSTEMS, INC. | 3,798,926 | $7.636M | 2.0% | $11.56 | — | COM | 82933R100 |
| — | UNITY BIOTECHNOLOGY, INC. | 1,004,817 | $2.753M | 0.7% | $0.40 | — | COM | 91381U200 |
| — | METACRINE, INC. | 2,940,503 | $1.317M | 0.3% | $0.61 | — | COM | 59101E103 |